Bristol-Myers Squibb's $74B deal for Celgene criticized, called risky
March 04, 2019 at 13:24 PM EST
At least one shareholder said the $74 billion deal is "poorly conceived and ill-advised."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|